RxDoctor Payments Data

Mark Richard, MD

Internal Medicine · Derry, NHNPI 1356435655

Payments from drug & device makers

$460in general payments, 2019–2025

Across 24 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$308
  • Gilead$49
  • Pfizer$39
  • GSK$25
  • Novo Nordisk$18
  • Lilly USA, LLC$14
  • plus $8 from 1 others

What the payments were for

  • Food & beverage$460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie16$308
Gilead2$49
Pfizer2$39
GSK1$25
Novo Nordisk1$18
Lilly USA, LLC1$14
Johnson & Johnson1$8

How this compares

$460 in reported general payments places this provider in the 85th percentile of 504 internal medicine providers in New Hampshire.

See all internal medicine providers in New Hampshire

Medicare billing

Part B allowed, 2024
$411,019
Medicare patients
893
Services billed
5,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$150,182
OzempicSemaglutide66$85,197
JardianceEmpagliflozin46$59,267
XareltoRivaroxaban28$36,049
JanuviaSitagliptin Phosphate18$25,952
TrulicityDulaglutide24$25,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,376
LinzessLinaclotide11$17,438
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$16,448
AmbienZolpidem Tartrate11$14,384
MounjaroTirzepatide11$14,294
Breo ElliptaFluticasone/Vilanterol18$9,646
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$8,508
Humalog Kwikpen U-100Insulin Lispro38$6,029
Atorvastatin Calcium673$5,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$150,182153 claims
Novo NordiskOzempic$18$85,19766 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$25$46,47080 claims
Lilly USA, LLCTrulicity, Mounjaro$14$39,57635 claims
Johnson & JohnsonXarelto$8$36,04928 claims
AbbVieLinzess, Synthroid$308$19,13153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 504 internal medicine providers in New Hampshire.

Other internal medicine in Derry

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →